Luis Martin, Co-founder and CEOScientists usually screen multiple candidates with closely related responses and therapeutic targets before selecting the one eligible for early-stage clinical trials. Traditionally, this process is marred by uncertainties due to the enormous datasets researchers had to manually sift through to gain relevant information on the biological mechanism of all molecules in the running.
CancerAppy is streamlining this approach with its state-of-the-art machine learning models and expert R&D team, which collectively simplify the identification and development of new, first-in-line cancer drugs.
Leveraging powerful algorithms to analyse numerous compounds, the company is known for its precise detection of potential drugs and ability to promptly validate them in-silico before approving laboratory evaluations. CancerAppy strategically narrows its focus to ten or fifteen compounds based on AI platform results, ensuring targeted, optimal, and resource-efficient development.
“Our algorithms analyse compounds, identify potential drug targets, and validate them in silica to ensure a smooth traversal through in-vitro and in-vivo evaluations. Our goal is to serve as a bridge between innovative drug discovery and pharmaceutical industry leaders,” says Luis Martin, co-founder and CEO of CancerAppy.
Beyond economic growth and market differentiation, first-in-class drugs significantly impact patient outcomes and advance scientific knowledge by addressing unmet medical needs.
Recognising the significance of cooperation in overcoming persistent drug discovery, development, and commercialisation hurdles, CancerAppy is looking to spark collaborations to develop disruptive treatments through co-development partnerships or by licensing new assets.
Founded in 2019 to address gaps in early-stage cancer research, the company tackles challenges stemming from the absence of efficient identification and validation methods for novel drug targets and biomarkers. Recognising the uncertainties in differentiating promising compounds from potential drugs, co-founder Alberto Ocaña envisioned CancerAppy as a foundation for optimising the R&D of first-in-line drugs. Over time, the duo of Martin and Ocaña assembled a team comprising seasoned researchers and adopted a global scoring system to ensure high drug performance and viable development frameworks.
AI tools have played a pivotal role in CancerAppy’s success since its early days. Today, the platform efficiently handles one billion compounds in three weeks, a feat once deemed impossible. While intelligent algorithms play a crucial role, the company emphasises the symbiosis between AI and the scientific expertise of its team. This approach strikes a balance between the technology’s accurate analysis and the researchers’ proficiency in interpretation.
Our algorithms analyse compounds, identify potential drug targets, and validate them in-silico to ensure a smooth traversal through in-vitro and in-vivo evaluations. Our goal is to serve as a bridge between innovative drug discovery and pharmaceutical industry leaders
The company’s focus extends to various cancer types, with its programs centred on breast and ovarian cancer, showing significant progress in the advanced R&D stages. Promising developments are also observed in lung and pancreatic cancer programs. CancerAppy anticipates initiating the preclinical phase for these studies within Q4 2023, showcasing a multifaceted approach to addressing distinct cancer types.
Established to reduce uncertainty in new cancer drug development, CancerAppy uniquely integrates biology, chemistry, AI, and computing expertise. Emphasising a parallel workflow, it works on obtaining in-silico and in-vitro results simultaneously to deliver optimised in-vivo testing. This comprehensive and efficient strategy reflects its obligation to integrate computational, laboratory, and animal-based testing, ensuring a cohesive and effective workflow across the entire R&D journey.
Driven by a collaborative spirit, cutting-edge technology, and a pledge to patient outcomes, CancerAppy is emerging as a key player in the evolution of cancer treatment and actively shaping the future of healthcare.
